18F-FDG PET/CT in assessment of paraneoplastic cerebellar degeneration as the first sign of occult fallopian tube serous cystadenocarcinoma: Case report

Background

18F-FDG PET/CT may be considered as a useful tool for the assessment of primary tumor detection in patients with paraneoplastic neurological syndromes (Opalińska, M, et al. J Clin Med, 2022. 11(6)). Besides, 18F-FDG PET/CT is a fast-track access to additional diagnostics among pre-treatment of gynecological cancers (Sponholtz, S.E., et al., Acta Obstet Gynecol Scand, 2020. 99(2): p. 186–195. Dejanovic, D., et al. Seminars in Nuclear Medicine, 2021. 51(6): p. 593–610.) Paraneoplastic neurological syndromes (PNS) are rare heterogeneous groups of neurological disorders associated with an underlying malignancy. (Rosenfeld, M.R. et al. Neurologic Clinics, 2018. 36(3): p. 675–685. Dalmau, J. et al. The Lancet Neurology, 2008. 7(4): p. 327–340). Paraneoplastic cerebellar degeneration (PCD) accounts for about one-fourth of PNS, which more frequently involves the cerebellum (Vogrig, A., et al. Journal of Neurology, 2020. 267(1): p. 26–35.) Diagnosis of PNS is challenging which may cause misdiagnosis and delay of treatment management may occur. Therefore, accurate and early identification of clinically suspected tumors causing PNS is crucial for optimal disease management and patient outcome (Maskery, M.P., et al. Front Neurol, 2017. 8: p. 238.).

Publikationsverlauf

Eingereicht: 29. August 2023

Angenommen nach Revision: 19. Februar 2024

Artikel online veröffentlicht:
16. April 2024